Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-25-041547
Filing Date
2025-11-12
Accepted
2025-11-12 07:23:37
Documents
81
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ef20054965_10q.htm   iXBRL 10-Q 1891108
2 EXHIBIT 10.3 ef20054965_ex10-3.htm EX-10.3 16798
3 EXHIBIT 31.1 ef20054965_ex31-1.htm EX-31.1 13026
4 EXHIBIT 31.2 ef20054965_ex31-2.htm EX-31.2 13280
5 EXHIBIT 32.1 ef20054965_ex32-1.htm EX-32.1 5985
  Complete submission text file 0001140361-25-041547.txt   9043344

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ird-20250930.xsd EX-101.SCH 81430
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ird-20250930_cal.xml EX-101.CAL 37072
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ird-20250930_def.xml EX-101.DEF 447726
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250930_lab.xml EX-101.LAB 923046
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250930_pre.xml EX-101.PRE 594485
84 EXTRACTED XBRL INSTANCE DOCUMENT ef20054965_10q_htm.xml XML 1298960
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 251468819
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)